GlassScriptPhysician profile
Kyle L Clifford
NPI 1841285590
$3,355.09
in general payments reported to CMS, 2019-2025
31 companies · $622 in 2025
The $622 reported for 2025 was more than what 77% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $259 · 2020: $160 · 2021: $422 · 2022: $803 · 2023: $511 · 2024: $579 · 2025: $622.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,711.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,711.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $849.10 | 2021-2025 | Ubrelvy, Qulipta |
| Amgen INC. | $498.19 | 2019-2025 | Evenity, Prolia |
| Lilly USA, LLC | $364.70 | 2020-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $255.51 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Astellas Pharma US INC | $167.85 | 2023-2025 | Veozah |
| Glaxosmithkline, LLC. | $137.47 | 2019-2023 | Bexsero, Shingrix, Pediarix |
| Astrazeneca Pharmaceuticals LP | $107.06 | 2019-2024 | Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $99.36 | 2021-2022 | |
| Sanofi Pasteur INC. | $92.14 | 2022-2025 | |
| Phathom Pharmaceuticals, INC. | $77.68 | 2024-2025 | Voquezna |
| Pfizer INC. | $75.59 | 2019-2025 | |
| Exact Sciences Corporation | $65.93 | 2023-2025 | Cologuard Collection Kit |
| Biohaven Pharmaceutical Holding Company LTD. | $57.14 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $51.43 | 2021 | |
| Xeris Pharmaceuticals, INC. | $46.72 | 2023-2025 | Gvoke Hypopen, Recorlev |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $46.19 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $44.37 | 2023-2025 | Spravato |
| Boston Scientific Corporation | $43.64 | 2019-2022 | |
| Tandem Diabetes Care, INC. | $41.16 | 2021-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Therapeuticsmd, INC. | $34.17 | 2021-2022 | |
| Vanda Pharmaceuticals INC. | $28.15 | 2024 | Fanapt |
| Abbott Laboratories | $23.67 | 2022 | |
| Viatris Specialty LLC | $21.42 | 2025 | Yupelri |
| Merck Sharp & Dohme LLC | $20.68 | 2025 | Verquvo |
| Tris Pharma INC | $20.22 | 2023 | Dyanavel Xr |
| Corcept Therapeutics | $17.29 | 2024 | Korlym |
| Nevro Corp. | $15.02 | 2020 | |
| Apria Healthcare LLC | $14.74 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.19 | 2020 | |
| Scynexis, INC. | $13.49 | 2021 | |
| Arbor Pharmaceuticals, INC. | $10.82 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kyle Clifford listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.